The Hematology Profiles of Adults Affiliated with Epilepsy after Receiving Valproic Acid Therapy

Authors

DOI:

https://doi.org/10.3889/oamjms.2023.11617

Keywords:

Hematology Profile, Valproic Acid, Epilepsy, Adults, Treatment safety

Abstract

AIM: Epilepsy is a socially significant neurological disease spread all over the world. Valproic acid (VPA) is one of the most used antiepileptic drug (AED) for treatment which has some side effects on hematology field. A nowadays update to the adult safety  information is needed. The current aim is to conduct a cross-sectional study and to describe the hematology profile of adults with epilepsy treated by VPA.

MATERIALS AND METHODS: Data collection was done retrospectively and includes characteristics of the subjects such as age, gender,  electroencephalography (EEG) finding, duration of VPA treatment, type of treatment, and hematology profile. We report 50 subjects treated by VPA at least 1 year.

RESULTS: The mean age is 46, 4 years, 50% male and 50% female. About 92% were generalized tonic-clonic seizure. Seven percent were partial complex epilepsy. Twenty-four EEG results were abnormal (48%). We found 4 cases (7%) of thrombocytopenia at therapeutic dose and 8 cases (16%) of mild anemia.

DISCUSSION: Gender differences were eliminated by having the same number of participants of each gender. The EEG findings were almost equally normal and abnormal. Reported drug reactions due to VPA were thrombocytopenia and anemia. Thrombocytopenia requires discontinuation of VPA.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Naydenov C, Yordanova A, Mancheva V. Methodology for EEG and reference values of the software analysis. Open Access Maced J Med Sci. 2022;10(B):2351-4. https://doi.org/10.3889/ oamjms.2022.10751 DOI: https://doi.org/10.3889/oamjms.2022.10751

Goldenberg MM. Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment. P T. 2010;35(7):392-415. PMid:20689626

Fagundes S. Valproic acid: Review. Rev Neurosci. 2008;16(2):130-6. DOI: https://doi.org/10.34024/rnc.2008.v16.8650

Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010;2010:479364. https://doi. org/10.1155/2010/479364 PMid:20798865 DOI: https://doi.org/10.1155/2010/479364

Putri Y, Mahalini D, Suwarba I. The hematology profiles of children affiliated with epilepsy at Sanglah hospital after receiving valproic acid therapy. Int Res J Med Med Sci. 2019;7(3):105-10. https://doi.org/10.30918/IRJMMS.73.19.055 DOI: https://doi.org/10.30918/IRJMMS.73.19.055

Verrotti A, Scaparrotta A, Grosso S, Chiarelli F, Coppola G. Anticonvulsant drugs and hematological disease. Neurol Sci. 2014;35(7):983-93. https://doi.org/10.1007/s10072-014-1701-0 PMid:24619070 DOI: https://doi.org/10.1007/s10072-014-1701-0

Downloads

Published

2023-05-23

How to Cite

1.
Naydenov C, Mindov I. The Hematology Profiles of Adults Affiliated with Epilepsy after Receiving Valproic Acid Therapy. Open Access Maced J Med Sci [Internet]. 2023 May 23 [cited 2024 Nov. 21];11(B):562-4. Available from: https://oamjms.eu/index.php/mjms/article/view/11617